Isis Pharmaceuticals announced today that Eli Lilly and Company licensed LY2275796, a second-generation antisense anti-cancer drug candidate for cli
Cytogen Corporation today announced the presentation of new data relating to its lead therapeutic product Quadramet (samarium Sm-153 lexidronam injection) during the 36th Congress of the
Maxim Pharmaceuticals today announced that its treatment protocol to provide its investigational drug Ceplene(TM), in combination with interleukin-2 (IL-2), for the treatment of patients with advanced malignant melanoma,
Researchers at the University of Pennsylvania School of Medicine have concluded the world's largest analysis of penicillin allergy due to re-prescription of the popular antibiotic. Their initial findings may eventual
HHS Secretary Tommy G. Thompson has announced the awarding of a contract to Aventis Pasteur Inc. to manufacture and store 2 million doses of avian influenza H5N1 vaccine, an important initial acquisit
A drug duo appears to be a safe and effective way to prevent a serious condition called graft-versus-host-disease (GVHD) in youngsters undergoing a stem cell transplant, researchers from Children's H
GlaxoSmithKline (GSK) has granted a voluntary licence under its patents to Cosmos Limited, a Kenyan pharmaceutical company, for the manufacture and sale of antiretrovirals (ARVs) containing zidovudine and
A landmark South African legal complaint against British drug maker GlaxoSmithKline (GSK) over its AIDS drug pricing and policies in that country will proceed after GSK dropped its public and repeated vows to appeal a decision allowing the case to go f
Pfizer and PA Consulting Group have announced the signing of a transaction in which Pfizer will purchase the remaining 90% ownership of
The Food and Drug Administration today announced the settlement of a court case against an Illinois firm involved last year in FDA's seizure of thousands of imported unapproved drugs, including those that were labeled i
Genencor International, Inc. today announced that it has agreed to sell its therapeutic vaccine program to Belgian biotechnology company Innogenetics N.V.
Innogenetics will develop and commercialize current product candidates in Genencor's vaccine product portfolio as well as future products based on intellectual property and technology held by Genencor.
Genencor will recognize license fees in the first year totaling $10 million, and will receive further payments of up to $87 million as development milestones are achieved. Genencor will also receive royalty payments on product sales. Genencor plans to apply the funds from this transaction towards building and advancing its Targeted Biotherapeutics pipeline focused initially in cancer.
Genencor launched its research initiative in therapeutic vaccines in 2001 and announced its plan to create innovative immunotherapeutic products for chronic diseases caused by hepatitis B, human papillomavirus and hepatitis C.
The portfolio today consists of a clinical product candidate for hepatitis B, a preclinical boost candidate for hepatitis B, a research-stage lead compound for human papillomavirus, and a discovery platform for future hepatitis C product candidates. Genencor filed an Investigational New Drug application (IND) for its hepatitis B product candidate in 2003, and recently began Phase I safety and immunogenicity testing.
Under the agreement, this product portfolio and discovery platform will be assumed by Innogenetics for additional research, development and commercialization. Genencor's research agreement and technology license from Epimmune Inc. will also be transferred as part of this transaction. After a short transition period with Genencor's assistance, Innogenetics will fully manage the current Phase I clinical study of the HBV vaccine candidate. Genencor may provide additional research or development services to Innogenetics on a funded basis.
"This agreement underscores our ability to deliver on our promise of creating significant value in our health care business in a relatively short period of time," said Genencor chairman, chief executive officer and president, Jean-Jacques Bienaimé. "We're pleased to put this valuable program in the hands of a solid company like Innogenetics with commercial experience in viral disease markets."
"This success is a result of a clear vision and superb execution by the experienced team we now have in place at Genencor," he added. "We are looking forward to applying that insight and expertise as we accelerate our efforts in therapeutics."
"Our ambition is to build a successful business based on innovative therapeutic products that serve medically and commercially important needs," said Mark A. Goldsmith, M.D., Ph.D., senior vice president, Health Care. "This transaction demonstrates that we have the capabilities needed to fulfill that ambition. Going forward, we are focusing our core competencies on delivering selective and potent Targeted Biotherapeutics engineered to provide effective and safe solutions to serious medical problems."
Goldsmith added, "We're particularly pleased with research progress in our primary focus area, oncology, and we expect to advance a Genencor lead compound for cancer into IND-enabling development during the first half of this year. In addition, we continue to pursue in-licensing of development-stage product candidates that complement our own discovery efforts."